At the current era of surrogacy of genetic profile and routine pathological feature of breast cancer, we identify HER2 HR+/− tumours as a subtype with high risk, presenting features and relatively poor clinical outcome possibly not very different from the increasingly recognized TN tumours. The gene discussed is ERBB2; the disease is neoplasm.